QUILT-3.078 trial: what clinicians have said so far
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
- NCT06061809 ↗
- Active, not recruiting
- ImmunityBio, Inc.
- Focused size, estimated: 1–150 verified statements once built
Discussed at: ESMO Congress 2026
We haven't built an HCP commentary report on QUILT-3.078 (recurrent or progressive glioblastoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on QUILT-3.078 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X, typically up to 31 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and Randomized Phase 2B Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields With or Without PD-L1 t-haNK in Participants With Recurrent or Progressive Glioblastoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Glioblastoma
- Interventions
- Bevacizumab; PD-L1 t-haNK; N-803; Tumor Treating Fields (TTFields, 200 kHz)
- Arms
- Single Arm · Experimental
- Experiment Treatment Arm A · Experimental
- Experiment Treatment Arm B · Experimental
- Enrollment
- 34 (estimated)
- Primary outcomes
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
- Incidence of clinically significant changes in comprehensive metabolic panel (CMP)
- Incidence of clinically significant changes in Hematology blood panel.
- Incidence of clinically significant changes in Urinalysis.
- 12-lead Electrocardiogram (ECG)
- Incidence of clinically significant changes in Temperature
- Incidence of clinically significant changes in Heart Rate
- Incidence of clinically significant changes in Respiratory Rate
- Incidence of clinically significant changes in Blood Pressure
- Incidence of clinically significant changes in Oxygen Saturation
- Neurological assessment to grade Immune effector cell-associated neurotoxicity syndrome (ICANS)
- Safety assessed by Cytokine Levels
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 7, 2024
- Primary completion
- Dec 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT06061809 · updated Jul 1, 2026